168. エーラス・ダンロス症候群 Ehlers-Danlos syndrome Clinical trials / Disease details
臨床試験数 : 13 / 薬物数 : 21 - (DrugBank : 11) / 標的遺伝子数 : 11 - 標的パスウェイ数 : 103
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05432466 (ClinicalTrials.gov) | November 7, 2022 | 21/6/2022 | Clinical Trial to Compare the Efficacy of Celiprolol to Placebo in Patients With Vascular Ehlers-Danlos Syndrome | A Phase 3 Randomized, Double-Blind, Decentralized Clinical Trial to Compare the Efficacy of Celiprolol to Placebo in the Treatment of Patients With COL3A1-Positive Vascular Ehlers-Danlos Syndrome | Vascular Ehlers-Danlos Syndrome | Drug: ACER-002 (celiprolol) 200 mg BID;Drug: Placebo BID | Acer Therapeutics Inc. | NULL | Recruiting | 15 Years | 64 Years | All | 150 | Phase 3 | United States |
| 2 | NCT00190411 (ClinicalTrials.gov) | October 2003 | 13/9/2005 | Celiprolol in Patients With Ehlers-Danlos Syndrome, Vascular Type | Prevention of Vascular Complications by BetaBlocker Treatment in Vascular Ehlers-Danlos Syndrome | EHLERS-DANLOS SYNDROME, TYPE IV, AUTOSOMAL DOMINANT;CHROMOSOME 2q31.2 DELETION SYNDROME | Drug: celiprolol;Drug: Control | Assistance Publique - Hôpitaux de Paris | Aventis Pharmaceuticals | Completed | 15 Years | 65 Years | Both | 54 | Phase 4 | France |